Searched for
CAMBRIDGE BIOTECH
US Stocks: Wave Life Sciences shares plunge 58% as data for high dose of obesity drug disappointsWave Life Sciences shares plunged 58% on Thursday after a higher dose of its experimental obesity drug failed to show a clear improvement a...- Moderna plans to lay off 10% of workforce to cut costsModerna is set to reduce its global workforce by roughly 10%, aiming for under 5,000 employees by year's end, as it accelerates cost-cuttin...
- Moderna layoffs: U.S. Pharma giant announces massive job cuts, to have less than 5,000 employees, MRNA stocks sinkModerna had said earlier this year it expects operating costs to be between $4.7 billion and $5 billion for 2027. MRNA stock, which has los...
- Semiconductor company Arm to open second office in Bengaluru“In Bangalore, we have about 2,000 people and we're just acquiring a new building to grow and make that even bigger and better,” said Peter...
- Moderna can make vaccine for Omicron by early next year“We should know about the ability of the current vaccine to provide protection in the next couple of weeks,” Burton said.
- BioNTech to build mRNA manufacturing site in SingaporeThe biotech company said the Singapore production facility will have an estimated annual capacity of several hundred million doses of mRNA-...
- Serum Institute to invest 240 million pounds in UK; leads cross-sector Indian investmentsThe Pune-based vaccine manufacturer is among a list of nearly 20 Indian companies across sectors such as healthcare, biotech and software s...
- Tata in talks to launch Moderna vaccine in IndiaTata Medical & Diagnostics, a newly formed subsidiary of Tata Sons, is said to have started initial discussions with US company Moderna for...
- Moderna mania draws bitcoin comparisons while shorts bleedModerna jumped as much as 17% in New York Tuesday. The stock has surged about 73% and added more than $28 billion in market value over the ...
- India in dialogue with Moderna, other biotech firms over progress in COVID vaccine development: SourcesModerna on Monday said the independent National Institutes of Health-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of...
- This $5 billion startup made its first Cancer vaccine - for just one personNovel cancer drugs often come with six-figure price tags, so success could be lucrative. Numerous companies are chasing a cancer vaccine. O...
- Biotech startups: Govt steps in where investors fear to treadA flagship government-funding programme has provided a springboard to India's biotechnology industry by backing innovative and risky projec...
- Are India’s life sciences startups turning a corner?A life sciences or medical product company is yet to make it big anywhere in India, despite a startup culture that is 15 years old.
- India signs biotech pact with Cambridge UniversityIndia has signed a pact with the UK's prestigious Cambridge University to create a new programme of early-career fellowships in the field o...
- Jeremy Levin named as next CEO of Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries Ltd named Jeremy Levin of Bristol-Myers Squibb Coto to replace Shlomo Yanai as chief executive officer.
- Dr Reddy's relocates Chirotech Tech Centre to Cambridge in UKIndia's leading pharmaceutical firm Dr Reddy's Laboratories has moved its UK subsidiary,Chirotech, to a new purpose built lab facility at t...
- Genzyme board rejects Sanofi $69-a-share offerBiotech firm Genzyme Corp. says its board of directors is rejecting Sanofi-Aventis SA's $69 a share offer and recommending Genzyme sharehol...
- Japan's Takeda in $8.8 billion bid for US biotech firmJapan's Takeda Pharmaceutical Co has agreed to pay about $8.8 billion for US biotech company Millennium Pharmaceuticals Inc, the two firms ...
- Long queue for GE Money businessThe race to acquire the personal and home loan portfolio of General Electric’s consumer finance company, GE Money Financial Services is hot...
- Big Pharma seeks biotech dose to spur growthVincent Aita of Kilkenny Capital Management says he picks biotechnology stocks on their potential as takeover targets.
Load More
